Piers Patten

15PUBLICATIONS
92CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesOtorhinolaryngologyMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Apr 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

|Mar 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Richard R Furman, William G Wierda, Piers Em Patten

|Mar 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

David J Allsup, David A Cairns, E Faye Samy

|Jul 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger, Paul M Barr, Tadeusz Robak

|Jun 25, 2025
Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer.

Bernd B Zeisig, Chiou-Tsun Tsai, Clemence Virely

|Dec 18, 2024
Proliferating CLL cells express high levels of CXCR4 and CD5.

Daniel Friedman, Drshika P Mehtani, Jennifer B Vidler

Pageof 3

Frequent Collaborators

3 joint publications

Toby A Eyre

3 joint publications

Nicolas Martinez-Calle

3 joint publications

Talha Munir

2 joint publications

Renata Walewska